Risk factors for severe PCR-positive SARS-CoV-2 infection in hospitalised children

Tilmann Schober,1 Chelsea Caya,2 Michelle Barton,3 Ann Bayliss,4 Ari Bitnun,5 Jennifer Bowes,6 Helena Brenes-Chacon,7 Jared Bullard,8 Suzette Cooke,9 Tammie Dewan,9 Rachel Dowlow,8 Tala El Tal,5 Cheryl Foo,10 Peter Gill,11 Behzad Haghighi Aski,11 Fatima Kakkar,12 Janell Lautermlilch,13 Marie-Astrid Lefebvre,1 Kirk Leifso,14 Nicole Le Saux,5 Alison Lopez,15 Ali Manafi,11 Joanna Merckx,16 Shaun K Morris,5 Alireza Nateghian,11 Luc Panetta,12 Dara Petel,3 Dominique Piché,17 Rupeena Purewal,13 Lea Restivo,9 Ashley Roberts,15,18 Manish Sadaranangi,18,19 Rosie Scuccimarri,1 Alejandro Soriano-Fallas,7 Sarah Tehseen,13 Karina A Top,17 Rolando Ulloa-Gutierrez,1,7 Isabelle Viel-Theriault,20 Jacqueline Wong,21 Carmen Yea,5 Ann Yeh,5 Adriana Yock-Corrales,7 Joan L Robinson,22 Jesse Papenburg1,2

ABSTRACT

Objective To identify risk factors for severe disease in children hospitalised for SARS-CoV-2 infection.

Design Multicentre retrospective cohort study.

Setting 18 hospitals in Canada, Iran and Costa Rica from 1 February 2020 to 31 May 2021.

Patients Children<18 years of age hospitalised for symptomatic PCR-positive SARS-CoV-2 infection, including PCR-positive multisystem inflammatory syndrome in children (MIS-C).

Main outcome measure Severity on the WHO COVID-19 Clinical Progression Scale was used for ordinal logistic regression analyses.

Results We identified 403 hospitalisations. Median age was 3.78 years (IQR 0.53–10.77). At least one comorbidity was present in 46.4% (187/403) and multiple comorbidities in 18.6% (75/403). Eighty-one children (20.1%) met WHO criteria for PCR-positive MIS-C. Progression to WHO clinical scale score ≥6 occurred in 25.3% (102/403). In multivariable ordinal logistic regression analyses adjusted for age, chest imaging findings, laboratory-confirmed bacterial and/or viral coinfection, and MIS-C diagnosis, presence of a single (adjusted OR (aOR) 1.90, 95% CI 1.13 to 3.20) or multiple chronic comorbidities (aOR 2.12, 95% CI 1.19 to 3.79), obesity (aOR 3.42, 95% CI 1.76 to 6.66) and chromosomal disorders (aOR 4.47, 95% CI 1.25 to 16.01) were independent risk factors for severity. Age was not an independent risk factor, but different age-specific comorbidities were associated with more severe disease in age-stratified adjusted analyses: cardiac (aOR 2.90, 95% CI 1.11 to 7.56) and non-asthma pulmonary disorders (aOR 3.07, 95% CI 1.26 to 7.49) in children<12 years old and obesity (aOR 3.69, 1.45–9.40) in adolescents≥12 years old. Among infants<1 year old, neurological (aOR 10.72, 95% CI 1.01 to 113.35) and cardiac disorders (aOR 10.13, 95% CI 1.69 to 60.54) were independent predictors of severe disease.

WHAT IS ALREADY KNOWN ON THIS TOPIC
⇒ Symptoms associated with SARS-CoV-2 infection are generally milder in children than in adults.
⇒ Severe courses can also occur in children and it is important to understand the risk factors for severity.
⇒ Several risk factors for severity have been identified, but the data are partly contradictory, especially with regard to age as risk factor among children.

WHAT THIS STUDY ADDS
⇒ Severe disease among children hospitalised for SARS-CoV-2 infection is associated with several risk factors including the presence of comorbidities, obesity and chromosomal disorders.
⇒ The risk profile and presence of comorbidities differ between paediatric age groups, but age itself is not associated with severe outcomes.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY
⇒ Improved understanding of paediatric risk factors for severe SARS-CoV-2 infection can help guide management and refine risk-benefit analyses of paediatric vaccination programmes against SARS-CoV-2.

Conclusion We identified risk factors for disease severity among children hospitalised for PCR-positive SARS-CoV-2 infection. Comorbidities predisposing children to more severe disease may vary by age. These findings can potentially guide vaccination programmes and treatment approaches in children.

INTRODUCTION

The clinical presentation of SARS-CoV-2 infection is generally milder in children than in adults. However, severe courses can also occur in children,1,2,3 and long-term sequelae have been described.4–6 Several risk factors for severity have been identified, but the data are partly contradictory, especially with regard to age as risk factor among children.1,3,7,8 Therefore, these findings can potentially guide vaccination programmes and treatment approaches in children.
adults. However, children can also experience morbidity and mortality due to COVID-19.\(^1\) Knowing the risk factors for severe disease allows for identification of patient groups that require closer monitoring or early treatment, and help guide targeted vaccination campaigns. While many countries started a vaccination programme against SARS-CoV-2 for all adolescents and children ≥5 years of age, others had limited access to vaccines or decided to

### Table 1

Baseline characteristics of patients with PCR-positive SARS-CoV-2 infection (N=403) according to country of origin

| Demographics | Canada n=266 (%) | Costa Rica n=107 (%) | Iran n=30 (%) | Total N=403 (%) |
|--------------|------------------|----------------------|--------------|----------------|
| Median age in years (IQR)* | 5.82 (0.84–14.27) | 2.19 (0.47–5.94) | 2.04 (0.67–5.96) | 3.78 (0.53–10.77) |
| Age≥30 days | 30 (11.3%) | 7 (6.5%) | 0 | 37 (9.2%) |
| Age category* | | | | |
| <1 year | 67 (25.3%) | 36 (34.0%) | 10 (33.3%) | 113 (28.2%) |
| 1–4 years | 58 (21.9%) | 40 (37.7%) | 8 (26.7%) | 106 (26.4%) |
| 5–11 years | 53 (20.0%) | 24 (22.6%) | 12 (40.0%) | 89 (22.2%) |
| ≥12 years | 87 (32.8%) | 6 (5.7%) | 0 | 93 (23.2%) |
| Male sex | 147 (55.3%) | 64 (59.8%) | 16 (53.3%) | 227 (56.3%) |

| Admission period | | | | |
| Prior to 1 July 2020 | 12 (4.5%) | 0 | 7 (23.3%) | 19 (4.7%) |
| Between 1 July 2020 and 31 December 2020 | 77 (28.9%) | 57 (53.3%) | 17 (56.7%) | 151 (37.5%) |
| Between 1 January 2021 and 31 May 2021 | 177 (66.5%) | 31 (29.0%) | 6 (20.0%) | 233 (57.8%) |

| Number of comorbidities | | | | |
| None | 140 (52.6%) | 61 (57.0%) | 15 (50.0%) | 216 (53.6%) |
| At least 1 comorbidity | 126 (47.4%) | 46 (43.0%) | 15 (50.0%) | 187 (46.4%) |
| 1 comorbidity | 68 (25.6%) | 31 (29.0%) | 13 (43.3%) | 112 (27.8%) |
| Multiple (≥2) comorbidities | 58 (21.8%) | 15 (14.0%) | 2 (6.7%) | 75 (18.6%) |

| Individual comorbidities† | | | | |
| Obesity | 44 (16.5%) | 5 (4.7%) | 1 (3.3%) | 50 (12.4%) |
| Pulmonary disorders | 32 (12.0%) | 20 (18.7%) | 2 (6.7%) | 54 (13.4%) |
| Non-asthma pulmonary disorders‡ | 16 (6.0%) | 4 (3.7%) | 2 (6.7%) | 22 (5.4%) |
| Asthma | 16 (6.0%) | 16 (14.9%) | 0 | 32 (7.9%) |
| Prematurity (<37 weeks’ gestational age) | 26 (9.8%) | 4 (3.7%) | 0 | 30 (7.4%) |
| Immunosuppression | 16 (6.0%) | 11 (10.3%) | 4 (13.3%) | 31 (7.7%) |
| Malignancy§ | 4 (1.5%) | 8 (7.5%) | 4 (13.3%) | 16 (4.0%) |
| Anaemia and/or haemoglobinopathy¶ | 13 (4.9%) | 0 | 0 | 13 (3.2%) |
| Sick cell anaemia | 6 (2.2%) | 0 | 0 | 6 (1.5%) |
| Neurological disorders** | 40 (15.0%) | 13 (12.1%) | 3 (10.0%) | 56 (13.9%) |
| Cardiac disorders | 11 (4.1%) | 6 (5.6%) | 2 (6.7%) | 19 (4.7%) |
| Metabolic disorders | 9 (3.4%) | 2 (1.9%) | 1 (3.3%) | 12 (3.0%) |
| Diabetes mellitus | 4 (1.5%) | 0 | 1 (3.3%) | 5 (1.2%) |
| Renal disorders | 8 (3.0%) | 3 (2.8%) | 3 (10.0%) | 14 (3.5%) |
| Hypertension | 6 (2.2%) | 3 (2.8%) | 0 | 9 (2.2%) |
| Chromosomal disorders†† | 6 (2.2%) | 2 (1.9%) | 0 | 8 (2.0%) |
| Others‡‡ | 18 (6.8%) | 5 (4.7%) | 2 (6.7%) | 25 (6.2%) |

*One child is listed from Canada and one child from Costa Rica being missing date of birth.
†Additional information is available for 14 out of 22 patients: obstructive sleep apnoea (n=5); bronchopulmonary dysplasia (n=3); pulmonary hypertension (n=2); cystic fibrosis (n=1); chronic aspiration pneumonia (n=1); subglottic stenosis (n=1); and Pierre-Robin anomaly (n=1).
§Additional information is available for 17 out of 22 patients: acute lymphoblastic leukaemia (n=11); neuroblastoma (n=2); lymphoma (n=1); rhabdomyosarcoma (n=1); and osteosarcoma (n=1).
¶Additional information is available for 13 out of 22 patients: sickle cell disease (n=6); glucose-6-phosphate dehydrogenase deficiency (n=2); anaemia of chronic disease (n=1); ovalocytosis (n=1); sickle cell disease (n=1); and iron deficiency anaemia (n=1).
**Additional information is available for 47 out of 56 patients: syndromic condition with global developmental delay (GDD) (n=19); autism and/or GDD of unexplained aetiology (n=10); cerebral palsy (n=7); muscular dystrophy (n=3); hydrocephalus (n=2); congenital microcephaly (n=2); brain tumour (n=1); focal cortical dysplasia (n=1); encephalopathy (n=1); and epilepsy (n=1).
††Additional information is available for 7 out of 8 patients: Trisomy 21 (n=3); unbalanced translocation (n=2); Prader-Willi syndrome (n=1); and Miller-Dieker syndrome (n=1).
‡‡Others consists of the following: gastrostomy (n=12); liver transplantation (n=2); coeliac disease (n=1); Crohn disease (n=1); failure to thrive (n=1); inflammatory bowel disease (n=1); inflammatory bowel disease and Hirschsprung disease (n=1); unclear liver disease (n=1); oesophageal atresia (n=1); scoliosis (n=2); liver cirrhosis and cholestasis (n=1); and Glanzmann thrombasthenia (n=1).
Table 2  Clinical characteristics, investigations, treatments and outcomes of patients with PCR-positive SARS-CoV-2 infection (N=403) according to country of origin

| Clinical features             | Canada n=266 (%) | Costa Rica n=107 (%) | Iran n=30 (%) | Total N=403 (%) |
|------------------------------|------------------|----------------------|---------------|----------------|
| Fever prior to or during admission* | 205 (82.3%) | 71 (78.0%) | 26 (92.8%) | 302 (82.1%) |
| Cough                        | 136 (51.1%) | 54 (50.5%) | 18 (60.0%) | 208 (51.6%) |
| Shortness of breath          | 125 (47.0%) | 55 (51.4%) | 8 (26.7%) | 188 (46.6%) |
| Vomiting                     | 91 (34.2%) | 22 (20.6%) | 14 (46.7%) | 127 (31.5%) |
| Rhinitis                     | 66 (24.8%) | 49 (45.8%) | 10 (33.3%) | 125 (31.0%) |
| Diarrhoea                    | 70 (26.3%) | 31 (29.0%) | 14 (46.7%) | 115 (28.5%) |
| Abdominal pain               | 67 (25.2%) | 26 (24.3%) | 15 (50.0%) | 108 (26.8%) |
| Headache                     | 47 (17.7%) | 19 (17.7%) | 6 (20.0%) | 72 (17.9%) |
| Rash                         | 42 (15.8%) | 24 (22.4%) | 3 (10.0%) | 69 (17.1%) |
| Conjunctivitis               | 46 (17.3%) | 21 (19.6%) | 1 (3.3%) | 68 (16.9%) |
| Myalgia                      | 30 (11.3%) | 12 (11.2%) | 18 (60.0%) | 60 (14.9%) |
| Pharyngitis                  | 32 (12.0%) | 15 (14.0%) | 13 (43.3%) | 60 (14.9%) |
| Wheeze                       | 16 (6.0%) | 26 (24.3%) | 12 (40.0%) | 54 (13.4%) |
| Chest pain                   | 32 (12.0%) | 3 (2.8%) | 4 (13.3%) | 39 (9.7%) |
| Cracked lips                 | 22 (8.3%) | 16 (14.9%) | 0 | 38 (9.4%) |
| Oedema of hands and feet    | 14 (5.3%) | 12 (11.2%) | 1 (3.3%) | 27 (6.7%) |
| Anosmia                      | 10 (3.7%) | 2 (1.9%) | 0 | 12 (3.0%) |
| Seizures                     | 6 (2.2%) | 3 (2.8%) | 2 (6.7%) | 11 (2.7%) |
| Coinfections                 |                |                      |               |                |
| Bacterial (positive cultures)† | 14 (5.3%) | 7 (6.5%) | 3 (10.0%) | 24 (5.9%) |
| Viral                        | 7 (2.6%) | 25 (23.4%) | 0 | 32 (7.9%) |
| Bacterial and/or viral       | 21 (7.9%) | 30 (28.0%) | 3 (10.0%) | 54 (13.4%) |
| Investigations               |                |                      |               |                |
| Chest imaging performed      | 200 (75.2%) | 82 (76.6%) | 30 (100.0%) | 312 (77.4%) |
| CXR and/or CT chest normal or had findings unrelated to COVID-19 | 60 (22.5%) | 45 (42.0%) | 16 (53.3%) | 121 (30.0%) |
| CXR and/or CT chest abnormalities compatible with COVID-19 | 140 (52.6%) | 37 (34.6%) | 14 (46.7%) | 191 (47.4%) |
| Laboratory investigations    |                |                      |               |                |
| Leucopenia (<4×109/L)‡       | 43 (17.1%) | 12 (11.5%) | 4 (13.3%) | 59 (15.3%) |
| Leucocytosis (>15×109/L)‡     | 20 (7.9%) | 21 (20.2%) | 6 (20.0%) | 47 (12.2%) |
| Neutropenia (<1.5×109/L)§     | 53 (21.4%) | 27 (26.0%) | 8 (26.7%) | 88 (23.0%) |
| Neutrophilia§                | 73 (29.4%) | 37 (35.6%) | 10 (33.3%) | 120 (31.4%) |
| Thrombocytopenia (<100×109/L)¶ | 27 (10.8%) | 12 (11.5%) | 5 (16.7%) | 44 (11.4%) |
| Thrombocytosis (>450×109/L)** | 47 (18.7%) | 29 (27.9%) | 10 (33.3%) | 86 (22.3%) |
| CRP >50 (mg/L)**             | 87 (38.7%) | 22 (25.0%) | 10 (33.3%) | 119 (34.7%) |
| Ferritin >500 (mcg/L)††      | 37 (28.2%) | 12 (37.5%) | 6 (30.0%) | 55 (30.0%) |
| Albumin <29 (g/L)‡‡          | 34 (45.9%) | 10 (21.7%) | 2 (6.7%) | 46 (34.8%) |
| Treatments                   |                |                      |               |                |
| Intravenous immunoglobulin   | 48 (18.0%) | 22 (20.6%) | 12 (40.0%) | 82 (20.3%) |
| Antiviral agent for influenza| 4 (1.5%)  | 0 | 4 (13.3%) | 8 (2.0%) |
| Corticosteroids              | 130 (48.9%) | 30 (28.0%) | 8 (26.7%) | 168 (41.7%) |
| Lopinavir-ritonavir           | 0 | 0 | 8 (26.7%) | 8 (2.0%) |
| Remdesivir                   | 35 (13.1%) | 0 | 6 (20.0%) | 41 (10.2%) |

Continued
focus on high-risk groups following WHO recommendations.\textsuperscript{2,3}

Previous studies have attempted to identify risk factors for severe disease in paediatric patients for severe SARS-CoV-2 infection.\textsuperscript{4–15} Some risk factors such as presence of comorbidities, obesity and increased inflammatory markers have been implicated,\textsuperscript{5,8,10–13,15,16} but many studies were small and there is substantial heterogeneity.\textsuperscript{17} Importantly, most major studies were from high-income countries, and data from low-income and middle-income countries are scarce.

The aim of this study was the identification of risk factors for severe disease in children hospitalised for symptomatic PCR-confirmed SARS-CoV-2 infection including PCR-positive multisystem inflammatory syndrome in children (MIS-C) in a multicentre retrospective cohort study from Canada, Costa Rica and Iran.

**METHODS**

**Study design and data collection**

Sixteen paediatric hospitals from the Canadian Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) group and two international collaborators from Tehran, Iran and San José, Costa Rica identified all children <18 years of age admitted from 1 February 2020 through 31 May 2021 for PCR-positive SARS-CoV-2 infection or PCR-confirmed MIS-C. Patients who were admitted for reasons other than their SARS-CoV-2 infection (ie, incidental infections), as per each local investigator’s adjudication, were excluded. Data on primary indication for admission, demographics, comorbidities, clinical presentation and course, coinfections, treatments and complications were abstracted by the investigators from the patient’s medical charts and managed using REDCap electronic data capture tools.\textsuperscript{18,19}

| Table 2 Continued |
|-------------------|
|                  | Canada n=266 (%) | Costa Rica n=107 (%) | Iran n=30 (%) | Total N=403 (%) |
| Azithromycin      | 0               | 0                   | 13 (43.3%)   | 13 (3.2%)       |
| Hydroxychloroquine| 1 (0.4%)        | 0                   | 23 (76.7%)   | 24 (5.9%)       |

**Highest level of care required**

|                          | Canada n=266 (%) | Costa Rica n=107 (%) | Iran n=30 (%) | Total N=403 (%) |
|--------------------------|------------------|---------------------|--------------|-----------------|
| No supplemental oxygen or ICU admission | 137 (51.5%) | 38 (35.5%) | 18 (60.0%) | 193 (47.9%) |
| Supplemental oxygen but no ICU admission§§ | 47 (17.7%) | 46 (43.0%) | 2 (6.7%) | 95 (23.6%) |
| ICU admission            | 82 (30.8%)      | 23 (21.5%)          | 10 (33.3%)   | 115 (28.5%)    |
| ICU without CPAP/BiPAP/MV| 45 (16.9%)      | 11 (10.3%)          | 6 (20.0%)    | 62 (15.4%)     |
| ICU with CPAP/BiPAP      | 18 (6.8%)       | 2 (1.9%)            | 0            | 20 (5.0%)      |
| ICU with MV              | 19 (7.1%)       | 10 (9.3%)           | 4 (13.3%)    | 33 (8.2%)      |
| Extracorporeal life support | 0              | 0                   | 0            | 0               |

**Complications**

|                  | Canada n=266 (%) | Costa Rica n=107 (%) | Iran n=30 (%) | Total N=403 (%) |
|------------------|------------------|---------------------|--------------|-----------------|
| MIS-C diagnosis  | 59 (22.2%)       | 19 (17.7%)          | 3 (10.0%)    | 81 (20.1%)      |

**Outcomes**

|                        | Canada n=266 (%) | Costa Rica n=107 (%) | Iran n=30 (%) | Total N=403 (%) |
|------------------------|------------------|---------------------|--------------|-----------------|
| Mean length of hospitalisation in days (SD)¶¶ | 5.9 (6.0) | 6.5 (8.1) | 9.3 (6.6) | 6.3 (6.7) |
| Median length of hospitalisation in days (IQR) | 4.0 (2.0–7.0) | 4.0 (3.0–7.0) | 7.0 (6.0–9.0) | 4.0 (2.0–7.0) |
| Death                  | 2 (0.7%)         | 3 (2.8%)            | 1 (3.3%)     | 6 (1.5%)        |
| Severe disease according to WHO clinical scale score ≥6 | 71 (26.7%) | 27 (25.2%) | 4 (13.3%) | 102 (25.3%) |

\*A total of 35 children were missing data on fever prior to or during admission (17 from Canada, 16 from Costa Rica and 2 from Iran) resulting in a total N of 368.

†Children with one of the following are included: blood culture thought to be truly positive and/or positive endotracheal tube cultures treated with antibiotics for presumptive bacterial pneumonia and/or positive bacterial culture from another site treated with antibiotics.

‡A total of 17 children were missing leucocyte values (14 from Canada and 3 from Costa Rica) resulting in a total N of 386.

§A total of 21 children were missing neutrophil values (18 from Canada and 3 from Costa Rica) resulting in a total N of 382. Cut-off values for neutrophilia are age dependent.

¶¶A total of 18 children were missing platelet values (15 from Canada and 3 from Costa Rica) resulting in a total N of 385.

††The variable assessing highest ferritin value used and a total of 220 children were missing a value (135 from Canada, 75 from Costa Rica and 10 from Iran) resulting in a total N of 183.

‡‡A total of 271 children were missing albumin values (192 from Canada, 61 from Costa Rica and 18 from Iran) resulting in a total N of 132.

§§Supplemental oxygen but no ICU admission includes those on oxygen, high flow nasal cannula, CPAP/BiPAP on regular or COVID-19 wards.

BiPAP, bilevel positive airway pressure; CPAP, continuous positive airway pressure; CRP, C-reactive protein; CXR, chest X-ray; ICU, intensive care unit; MIS-C, multisystem inflammatory syndrome in children; MV, mechanical ventilation.
hypothesis-driven and biologically plausible comparisons; accordingly, correction for multiple hypothesis testing was not done. Ordinal logistic regression analyses were performed with the WHO Clinical Progression Scale as an integer to determine crude and adjusted ORs (aORs) and corresponding 95% CIs for factors associated with more severe disease. To investigate the association of specific individual comorbidities and disease severity, separate multivariable models were created for each individual comorbidity. Covariates considered potential confounders based on literature and clinical experience were included a priori: age, chest imaging findings, laboratory-confirmed bacterial and/or viral coinfection, and MIS-C diagnosis. We adjusted for age using cubic splines. Further to explore the association of age with the outcome, age was categorised as ≤1 year, 1–4 years, 5–11 years and ≥12 years in separate analyses. Prespecified age-stratified analyses were also performed. Patients were excluded from the corresponding analyses in case of missing data points.

The Strengthening the Reporting of Observational studies in Epidemiology (STROBE) guidelines were followed. There was no patient, parental or public involvement at any stage of this study.

RESULTS
From 1 February 2020 through 31 May 2021, 982 children<18 years of age hospitalised for SARS-CoV-2-related illness and/or PCR-positive MIS-C were reported by the 18 study hospitals. We excluded 579 cases in whom SARS-CoV-2 was not confirmed by molecular testing from respiratory specimens or because the patient was admitted for non-SARS-CoV-2-related reasons. We included the remaining 403 hospitalisations (figure 1).

Demographics and clinical characteristics
Hospitalisations occurred from 19 March 2020 through 31 May 2021; 266 cases (66.0%) were from Canada, 107 (26.5%) from Costa Rica and 30 (7.4%) from Iran (tables 1 and 2). Overall median age was 3.78 years (IQR 0.53–10.77). At least one chronic comorbidity was present in 46.4% and multiple comorbidities in 18.6% of children. Fever (82.1%), cough (51.6%), shortness of breath (46.6%) and vomiting (31.5%) were the most common presenting symptoms. Intensive care unit (ICU) admission was required in 115 patients (28.5%). Six patients died, all with comorbidities, including 2 patients with malignancies receiving palliative care.

Compared with the two middle-income countries, cases from Canada were older (median 5.82 (IQR 0.84–14.27) vs 2.15 (IQR 0.48–6.01) years) with a higher proportion of adolescents (32.8% vs 4.4%, p<0.001) and occurred later during the study period (66.5% vs 40.9% admitted in 2021, p<0.001). Other key demographic, clinical and outcome parameters were similar between countries.

Predictors of disease severity
Univariable ordinal logistic regression ORs for the primary outcome of severity along the WHO Clinical

Variables of interest and study definitions
The primary outcome was severity of PCR-positive SARS-CoV-2 infection on the ordinal WHO Clinical Progression Scale (online supplemental table 1). Given the inclusion criterion of hospitalisation, all patients had a score of ≥4. As a secondary outcome, we used the WHO Clinical Progression Scale in a categorical fashion with a score of ≥6 for severe disease, that is, oxygen by non-invasive ventilation or high flow or mechanical ventilation or vasopressors or death. Baseline exposure variables (including the presence of chronic comorbidities: neurological, cardiac, pulmonary (also subcategorised into asthma; non-asthma pulmonary disease), metabolic, renal, and chromosomal disorders, immunosuppression (including malignancy), obesity, prematurity (<37 weeks gestational age), anaemia and/or haemoglobinopathy and ‘other’ comorbidities which included patients who could not be classified into the previous categories) and additional predictor variables are shown in tables 1 and 2 and described in detail in the online supplementary methods.

Data analysis
Data were analysed using R V.3.5.2 (R Core Team, Vienna, Austria) and STATA V.17.0 (StataCorp, College Station, Texas, USA). Statistical significance was assessed by using two-tailed tests, with an α of 0.05. Baseline and demographic characteristics were summarised using frequencies, percentages, means and SD, medians, and IQRs. Categorical data were compared using χ² or Fisher’s exact test as appropriate and continuous data compared using Wilcoxon rank-sum test. Statistical testing was limited to
Table 3  Characteristics of patients with PCR-positive SARS-CoV-2 infection (N=403) according to severity of disease (WHO COVID-19 Clinical Progression Scale of ≥6) and univariable ordinal logistic regression ORs for more severe disease along WHO COVID-19 Clinical Progression Scale

| Demographics | Mild/moderate disease n=301 (%) | Severe disease n=102 (%) | P value* | Unadjusted OR of more severe disease† |
|---------------|---------------------------------|--------------------------|----------|-------------------------------------|
| Median age in years (IQR)‡ | 3.21 (0.31–9.87) | 6.69 (1.31–13.46) | 0.002 | – |
| Age≤30 days | 34 (11.3%) | 3 (2.9%) | 0.009 | 0.56 (0.29–1.08) |
| Age category‡ | | | | |
| <1 year | 94 (31.4%) | 19 (18.6%) | 0.025 | Ref. |
| 1–4 years | 79 (26.4%) | 27 (26.5%) | 1.63 (0.98–2.70) |
| 5–11 years | 66 (22.1%) | 23 (22.5%) | 1.66 (0.97–2.84) |
| ≥12 years | 60 (20.1%) | 33 (32.3%) | 2.23 (1.34–3.73) |
| Male sex | 171 (56.8%) | 56 (54.9%) | 0.826 | 0.95 (0.66–1.38) |
| Admission period | | | | |
| Prior to 1 July 2020 | 16 (5.3%) | 3 (2.9%) | 0.262 | Ref. |
| Between 1 July 2020 and 31 December 2020 | 118 (39.2%) | 33 (32.3%) | 1.60 (0.61–4.22) |
| Between 1 January 2021 and 31 May 2021 | 167 (55.5%) | 66 (64.7%) | 1.70 (0.66–4.42) |
| Admitted in Canada | 195 (64.8%) | 71 (69.6%) | 0.442 | 0.75 (0.51–1.09) |

| Number of comorbidities | | | | |
| None | 173 (57.5%) | 43 (42.1%) | 0.009 | Ref. |
| 1 comorbidity | 81 (26.9%) | 31 (30.4%) | 1.61 (1.05–2.48) |
| Multiple (>2) comorbidities | 47 (15.6%) | 28 (27.4%) | 2.58 (1.59–4.18) |

| Individual comorbidities§ | | | | |
| Obesity | 25 (8.3%) | 25 (24.5%) | <0.001 | 4.72 (2.29–9.73) |
| Pulmonary disorders | 35 (11.6%) | 19 (18.6%) | 0.104 | 2.60 (1.59–4.24) |
| Non-asthma pulmonary disorders¶ | 12 (4.0%) | 10 (9.8%) | 0.047 | 3.11 (1.47–6.57) |
| Asthma | 23 (7.6%) | 9 (8.8%) | 0.865 | 2.01 (1.11–3.64) |
| Prematurity (<37 weeks’ gestational age) | 20 (6.6%) | 10 (9.8%) | 0.405 | 1.35 (0.68–2.66) |
| Immunosuppression | 26 (8.6%) | 5 (4.9%) | 0.284 | 0.31 (0.13–0.74) |
| Malignancy** | 15 (5.0%) | 1 (1.0%) | 0.083 | 0.07 (0.01–0.51) |
| Anaemia or haemoglobinopathy†† | 7 (2.3%) | 6 (5.9%) | 0.152 | 1.80 (0.61–5.29) |
| Sickle cell anaemia | 4 (1.3%) | 2 (2.0%) | 0.646 | 1.13 (0.25–5.24) |
| Neurological disorders‡‡ | 33 (11.0%) | 23 (22.5%) | 0.006 | 2.04 (1.22–3.41) |
| Cardiac disorders | 13 (4.3%) | 6 (5.9%) | 0.709 | 1.57 (0.69–3.59) |
| Metabolic disorders | 8 (2.6%) | 4 (3.9%) | 0.509 | 1.82 (0.55–6.04) |
| Diabetes mellitus | 3 (1.0%) | 2 (2.0%) | 0.604 | 2.38 (0.54–10.42) |
| Renal disorders | 9 (3.0%) | 5 (4.9%) | 0.357 | 1.55 (0.57–4.24) |
| Hypertension | 4 (1.3%) | 5 (4.9%) | 0.049 | 2.83 (0.84–9.53) |
| Chromosomal disorders§§ | 3 (1.0%) | 5 (4.9%) | 0.027 | 3.60 (1.02–12.63) |
| Others¶¶ | 17 (5.6%) | 8 (7.8%) | 0.578 | 1.76 (0.88–3.50) |

Clinical features

Continued
|                              | Mild/moderate disease | Severe disease | P value* | Unadjusted OR of more severe disease† |
|------------------------------|-----------------------|----------------|----------|--------------------------------------|
| Fever prior to or during admission*** | 226 (81.3%) | 76 (84.4%) | 0.604 | 0.96 (0.63–1.46) |
| Cough                        | 147 (48.8%) | 61 (59.8%) | 0.071 | 1.93 (1.33–2.81) |
| Shortness of breath          | 110 (36.5%) | 78 (76.5%) | <0.001 | 10.60 (6.83–16.45) |
| Vomiting                     | 91 (30.2%)  | 36 (35.3%) | 0.408 | 1.01 (0.68–1.51) |
| Rhinitis                     | 97 (32.2%)  | 28 (27.4%) | 0.437 | 0.93 (0.63–1.37) |
| Diarrhoea                    | 87 (28.9%)  | 28 (27.4%) | 0.878 | 1.04 (0.69–1.56) |
| Abdominal pain               | 80 (26.6%)  | 28 (27.4%) | 0.966 | 0.80 (0.52–1.23) |
| Headache                     | 52 (17.3%)  | 20 (19.6%) | 0.703 | 1.20 (0.75–1.94) |
| Rash                         | 50 (16.6%)  | 19 (18.6%) | 0.753 | 0.86 (0.51–1.45) |
| Conjunctivitis               | 46 (15.3%)  | 22 (21.6%) | 0.189 | 1.24 (0.75–2.06) |
| Myalgia                      | 46 (15.3%)  | 14 (13.7%) | 0.825 | 1.06 (0.64–1.76) |
| Pharyngitis                  | 50 (16.6%)  | 10 (9.8%)  | 0.131 | 0.77 (0.46–1.29) |
| Wheeze                       | 37 (12.3%)  | 17 (16.7%) | 0.341 | 2.16 (1.34–3.49) |
| Chest pain                   | 27 (9.0%)   | 12 (11.8%) | 0.528 | 1.39 (0.76–2.52) |
| Cracked lips                 | 26 (8.6%)   | 12 (11.8%) | 0.461 | 1.14 (0.59–2.20) |
| Oedema of hands and feet     | 19 (6.3%)   | 8 (7.8%)   | 0.760 | 1.25 (0.59–2.64) |
| Anosmia                      | 10 (3.3%)   | 2 (2.0%)   | 0.738 | 0.85 (0.30–2.44) |
| Seizures                     | 6 (2.0%)    | 5 (4.9%)   | 0.155 | 1.73 (0.55–5.45) |

**Coinfections**

|                              | Mild/moderate disease | Severe disease | P value* | Unadjusted OR of more severe disease† |
|------------------------------|-----------------------|----------------|----------|--------------------------------------|
| Bacterial (positive cultures)††† | 14 (4.6%) | 10 (9.8%) | 0.097 | 2.00 (0.93–4.30) |
| Viral                        | 15 (5.0%)  | 17 (16.7%) | <0.001 | 4.10 (2.22–7.58) |
| Bacterial and/or viral       | 29 (9.6%)  | 25 (24.5%) | <0.001 | 3.23 (1.94–5.39) |

**Investigations**

|                              | Mild/moderate disease | Severe disease | P value* | Unadjusted OR of more severe disease† |
|------------------------------|-----------------------|----------------|----------|--------------------------------------|
| No chest imaging done        | 89 (29.6%) | 2 (2.0%)   | <0.001 | 0.12 (0.05–0.28) |
| CXR and/or CT chest normal or had findings unrelated to COVID-19 | 102 (33.9%) | 19 (18.6%) | Ref. |
| CXR and/or CT chest abnormalities compatible with COVID-19 | 110 (36.5%) | 81 (79.4%) | 3.63 (2.32–5.67) |

**Laboratory investigations**

|                              | Mild/moderate disease | Severe disease | P value* | Unadjusted OR of more severe disease† |
|------------------------------|-----------------------|----------------|----------|--------------------------------------|
| Leucopenia (<4×10⁹/L)†††      | 47 (16.5%) | 12 (11.9%) | 0.344 | 0.66 (0.39–1.11) |
| Leucocytosis (>15×10⁹/L)†††   | 33 (11.6%) | 14 (13.9%) | 0.670 | 1.23 (0.70–2.18) |
| Neutropenia (<1.5×10⁹/L)§§§  | 69 (24.5%) | 15 (14.8%) | <0.001 | 0.55 (0.34–0.87) |
| Normal neutrophil count§§§   | 145 (51.6%) | 37 (36.6%) | Ref. |
| Neutrophilia§§§               | 67 (23.8%) | 49 (48.5%) | 2.59 (1.67–4.01) |
| Thrombocytopenia (<100×10⁹/L)¶¶¶ | 29 (10.2%) | 13 (12.9%) | 0.275 | 1.14 (0.61–2.13) |
| Normal platelet count¶¶¶     | 199 (70.1%) | 62 (61.4%) | Ref. |
| Thrombocytosis (>450×10⁹/L)¶¶¶ | 56 (19.7%) | 26 (25.7%) | 1.14 (0.71–1.82) |
| CRP not done****             | 51 (16.9%) | 9 (8.8%)  | 0.003 | Ref. |
| Normal CRP****               | 174 (57.8%) | 50 (49.0%) | 1.46 (0.84–2.53) |

Continued
Progression Scale are presented in table 3. Presence of 1 and of >1 comorbidity was associated with disease severity. Individually, obesity, pulmonary, neurological and chromosomal disorders were significant risk factors. In contrast, immunosuppression and its subcategory malignancy were associated with decreased risk (table 3). Shortness of breath, cough and wheeze were the clinical presentations associated with severity. Among laboratory and imaging investigations, viral coinfection, chest imaging compatible with COVID-19, neutrophilia, increased C-reactive protein (CRP), increased ferritin and low albumin were statistically significant risk factors.

Multivariable ordinal logistic regression analyses adjusting for age, coinfection, chest imaging and MIS-C demonstrated that obesity (aOR 3.42, 95% CI 1.76 to 6.66) and chromosomal disorders (aOR 4.47, 95% CI 2.15–6.66) were associated with increased risk of more severe disease.
1.25 to 16.01) were independent predictors of severe disease (figure 2A). In a separate model adjusting for the same covariates, we examined the effect of the number of comorbidities instead of each comorbidity individually. The presence of a single comorbidity (aOR 1.90, 95% CI 1.13 to 3.20) and of multiple comorbidities (aOR 2.12, 95% CI 1.19 to 3.79) were significant risk factors.

While adolescents ≥12 years of age had a higher risk of severe disease in univariable analysis (table 3), age as a categorical variable (figure 2B) and age modelled as a cubic spline (figure 3B) did not demonstrate a statistically significant association with disease severity.

In adjusted age-stratified analyses, among children <12 years, the individual comorbidities associated with severity were pulmonary disorders (aOR 2.53, 95% CI 1.20 to 4.51), especially non-asthma pulmonary disorders (aOR 3.07, 95% CI 1.26 to 7.49) and cardiac disorders (aOR 2.90, 95% CI 1.11 to 7.56; table 4). Among adolescents ≥12 years of age, the only comorbidity associated with severity was obesity (aOR 3.69, 95% CI 1.45 to 9.40). Of note, risk factors were not equally distributed between the two age groups. More adolescents had any (66.7% vs 40.2%, p<0.001) or multiple (25.8% vs 16.5%, p=0.049) comorbidities than younger children; obesity was markedly more common in adolescents (40.9% vs 3.9%, p<0.001). Among infants <1 year of age, neurological (aOR 10.72, 95% CI 1.01 to 113.35) and cardiac disorders (aOR 10.13, 95% CI 1.69 to 60.54) were independent predictors of severe disease.

The secondary disease severity outcome (WHO COVID-19 Clinical Progression Scale ≥6) occurred in 102 (25.3%) of 403 children (table 3). In univariable analysis, patients with severe disease were older (median 6.69 (IQR 1.31–13.46) vs 3.21 (IQR 0.31–9.87) years,
The proportion of children with severe disease increased progressively with age, with the lowest prevalence in neonates (8.1%) and the highest in ≥12 years old (35.5%). Compared with previously healthy patients, those with 1 or ≥2 comorbidities were more likely to have severe disease (19.9%, 31.5% and 37.3%, respectively; p=0.009).

**DISCUSSION**

In this multicentre cohort study from three countries, we identified risk factors for severe disease among children admitted to hospital for PCR-positive SARS-CoV-2 infection. Previous studies have been either limited to administrative data, were smaller or had a different scope. We confirmed several previously described risk factors for severity including the presence of one or more comorbidities, obesity, neurological, pulmonary and chromosomal disorders.

Previous studies have described a bimodal age pattern regarding severe disease, with a first peak in the very young and a second increase in adolescence mimicking global non-SARS-CoV-2-related childhood mortality. Infants in our study population were over-represented compared with the general paediatric population. For Canadian children, the proportion of infants was 4.3 times higher than its share of the population, suggesting a higher probability of hospitalisation. It is likely that some young infants with mild symptoms were admitted for observation, especially early during the pandemic. We did not see a higher rate of severe courses according to age, in line with other studies which restricted their analysis to hospitalised children.

Similar to other studies, we saw a higher proportion of severe disease in adolescents in our univariable analysis, but this was not confirmed in the multivariable models. This age group had a different risk profile than younger children. We found evidence that the comorbidities predisposing children to more severe disease may vary by age. While pulmonary (especially non-asthma disorders) and cardiac disorders were strongly associated with severe disease in children under 12 years old, neurological and cardiac disorders were risk factors in infants<1 year old, and only obesity predicted severe disease in adolescents. Two recent studies from the USA also observed that obesity was an independent risk factor for critical illness in adolescents but not younger children. This association more closely resembles adults, in whom metabolic risk factors are among the most important. The observed higher proportion of severe cases among adolescents in crude analyses could be mainly due to the markedly higher prevalence of obesity (40.9% in adolescents vs 3.9% in younger children in our study) and other comorbidities.

Our primary outcome using an ordinal scale differed from many previous studies which defined severity as ICU admission. ICU admissions are simple to measure, but can be problematic as a severity outcome because of heterogeneity across study sites due to dependence on local healthcare delivery structures and practice. In addition, patients with some comorbidities or within certain age categories may be admitted to ICU mainly for monitoring or for treatment of a condition independent of the severity of the current illness. In our dataset, 10 patients with high flow nasal cannula and/or non-invasive ventilation were managed outside of an ICU; in contrast, 26 patients in the ICU did not require mechanical or medical support of vital functions. Using ICU admission alone to define severity would have obscured the effect of several important risk factors. Therefore, we used the more objective WHO COVID-19 Clinical Progression Scale.

We confirmed several previously described risk factors for severity including the presence of one or more comorbidities, obesity, neurological, pulmonary and chromosomal disorders.

Previous studies have described a bimodal age pattern regarding severe disease, with a first peak in the very young and a second increase in adolescence mimicking global non-SARS-CoV-2-related childhood mortality. Infants in our study population were over-represented compared with the general paediatric population. For Canadian children, the proportion of infants was 4.3 times higher than its share of the population, suggesting a higher probability of hospitalisation. It is likely that some young infants with mild symptoms were admitted for observation, especially early during the pandemic. We did not see a higher rate of severe courses according to age, in line with other studies which restricted their analysis to hospitalised children.

Similar to other studies, we saw a higher proportion of severe disease in adolescents in our univariable analysis, but this was not confirmed in the multivariable models. This age group had a different risk profile than younger children. We found evidence that the comorbidities predisposing children to more severe disease may vary by age. While pulmonary (especially non-asthma disorders) and cardiac disorders were strongly associated with severe disease in children under 12 years old, neurological and cardiac disorders were risk factors in infants<1 year old, and only obesity predicted severe disease in adolescents. Two recent studies from the USA also observed that obesity was an independent risk factor for critical illness in adolescents but not younger children. This association more closely resembles adults, in whom metabolic risk factors are among the most important. The observed higher proportion of severe cases among adolescents in crude analyses could be mainly due to the markedly higher prevalence of obesity (40.9% in adolescents vs 3.9% in younger children in our study) and other comorbidities.

Our primary outcome using an ordinal scale differed from many previous studies which defined severity as ICU admission. ICU admissions are simple to measure, but can be problematic as a severity outcome because of heterogeneity across study sites due to dependence on local healthcare delivery structures and practice. In addition, patients with some comorbidities or within certain age categories may be admitted to ICU mainly for monitoring or for treatment of a condition independent of the severity of the current illness. In our dataset, 10 patients with high flow nasal cannula and/or non-invasive ventilation were managed outside of an ICU; in contrast, 26 patients in the ICU did not require mechanical or medical support of vital functions. Using ICU admission alone to define severity would have obscured the effect of several important risk factors. Therefore, we used the more objective WHO COVID-19 Clinical Progression Scale.

Furthermore, to obviate the need for a cut-off, which can be arbitrary, we used ordinal logistic regression to measure associations with more severe disease.
| Covariates                              | Model 1*: Children<1 year old (n=113) aOR (95% CI) | Model 2*: Children<1 year old (n=113) aOR (95% CI) | Model 3†: Children<12 years old (n=308) aOR (95% CI) | Model 4†: Children<12 years old (n=308) aOR (95% CI) | Model 5†: Children≥12 years old (n=93) aOR (95% CI) | Model 6†: Children≥12 years old (n=93) aOR (95% CI) |
|----------------------------------------|--------------------------------------------------|--------------------------------------------------|---------------------------------------------------|---------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
| **Number of comorbidities**            |                                                 |                                                 |                                                   |                                                   |                                                 |                                                 |
| None                                   | –                                                | Ref.                                             | –                                                 | Ref.                                              | –                                                | Ref.                                              |
| 1 comorbidity                          | –                                                | 1.72 (0.62 to 4.78)                              | –                                                 | 1.82 (0.98 to 3.36)                               | –                                                | 2.40 (0.79 to 7.30)                              |
| Multiple (>2) comorbidities            | –                                                | 2.16 (0.44 to 10.57)                             | –                                                 | 2.33 (1.18 to 4.63)                               | –                                                | 2.35 (0.68 to 8.17)                              |
| **Individual comorbidities**           |                                                 |                                                 |                                                   |                                                   |                                                 |                                                 |
| Obesity                                | 1.21 (0.14 to 10.70)                             | –                                                | 2.87 (0.96 to 8.55)                               | –                                                 | 3.69 (1.45 to 9.40)                               | –                                                 |
| Pulmonary disorders                    | 4.55 (0.87 to 23.82)                             | 2.33 (1.20 to 4.51)                              | –                                                 | 0.84 (0.28 to 2.58)                               | –                                                | –                                                 |
| Non-asthma pulmonary disorders         | 6.42 (0.95 to 43.18)                             | 3.07 (1.26 to 7.49)                              | –                                                 | 0.51 (0.09 to 2.96)                               | –                                                | –                                                 |
| Asthma                                 | N/A                                              | 1.42 (0.62 to 3.25)                              | –                                                 | 1.14 (0.32 to 4.06)                               | –                                                | –                                                 |
| Prematurity (<37 weeks’ gestational age)| 1.23 (0.36 to 4.20)                             | 1.13 (0.52 to 2.46)                              | –                                                 | 3.31 (0.35 to 31.24)                              | –                                                | –                                                 |
| Immunosuppression                      | –                                                | 0.45 (0.14 to 1.43)                              | –                                                 | 0.32 (0.05 to 2.05)                               | –                                                | –                                                 |
| Anaemia or haemoglobinopathy           | 1.51 (0.08 to 29.76)                             | 2.15 (0.61 to 7.52)                              | –                                                 | 1.37 (0.09 to 20.44)                              | –                                                | –                                                 |
| Neurological disorders                 | 10.72 (1.01 to 113.35)                           | 1.86 (0.87 to 3.97)                              | –                                                 | 1.71 (0.63 to 4.58)                               | –                                                | –                                                 |
| Cardiac disorders                      | 10.13 (1.69 to 60.54)                            | 2.90 (1.11 to 7.56)                              | –                                                 | –                                                 | –                                                | –                                                 |
| Metabolic disorders                    | –†                                               | 1.24 (0.24 to 6.34)                              | 1.61 (0.11 to 22.59)                              | –                                                 | –                                                | –                                                 |
| Renal disorders                        | –†                                               | 2.87 (0.92 to 8.97)                              | –                                                 | –                                                 | –                                                | –                                                 |
| Hypertension                           | –‡                                               | 3.04 (0.61 to 15.06)                             | 2.61 (0.23 to 29.36)                              | –                                                 | –                                                | –                                                 |
| Chromosomal disorders                  | 13.70 (0.68 to 274.79)                           | 3.30 (0.84 to 12.95)                             | –                                                 | –                                                 | –                                                | –                                                 |
| Others                                 | 3.48 (0.17 to 72.25)                             | 1.74 (0.68 to 4.45)                              | –                                                 | 0.82 (0.17 to 3.83)                               | –                                                | –                                                 |

*Model 1 incorporates each individual comorbidity in a separate ordinal logistic regression model, and model 2 incorporates the number of comorbidities while excluding individual comorbidities. Both models are adjusted for coinfection and chest imaging results.
†Models 3 and 5 incorporate each individual comorbidity in a separate ordinal logistic regression model, and models 4 and 6 incorporate the number of comorbidities while excluding individual comorbidities. All models are adjusted for age, coinfection, chest imaging results and MIS-C.
‡Too few occurrences/observations of this individual comorbidity in this age group resulting in a model error.
§No occurrences/observations of this individual comorbidity in this age group (n=0).
aOR, adjusted OR; MIS-C, multisystem inflammatory syndrome in children; NA, not appropriate (a diagnosis of asthma should not be made in an infant <1 year of age).
We decided to include all hospitalised symptomatic patients with positive SARS-CoV-2 PCR, independent of the diagnosis of MIS-C. Although the pathophysiology is different,\(^5\) it is frequently impossible to distinguish severe acute SARS-CoV-2 infections from PCR-positive MIS-C and both can be present at the same time.\(^2\) Thus, the strict separation of acute COVID-19 and early PCR-positive MIS-C may be an oversimplification. Moreover, treatment regimens for both conditions can overlap. Late, and typically PCR-negative, MIS-C has been shown to have different severity risk factors.\(^5\) By requiring patients to be PCR-positive, two-thirds of patients with MIS-C were excluded.

Our study has limitations. First, reporting may not have been uniform across centres despite the use of a study protocol and a standardised data capture tool. This includes but is not limited to the interpretation of chest radiographs, the definition of obesity and the severity of comorbidities. Second, despite being one of the largest paediatric cohort studies with more than 100 severe cases, the numbers of some individual comorbidities are small. This might overestimate or underestimate the impact of infrequent comorbidities such as anaemia and/or haemoglobinopathy, chromosomal or cardiac disorders. Third, laboratory investigations were not systematically performed. Complete blood counts, CRP and albumin values were missing in 4.2%, 14.9% and 67.2%, respectively. Moreover, laboratory investigations were done at the clinicians’ discretion, not at set time points during the illness. Other parameters previously described as risk factors could not be evaluated including ethnicity,\(^4\) which was not readily accessible from hospital records. In addition, viral sequencing data were not available. Fourth, indications for testing for SARS-CoV-2 likely varied by centre and over time, which might have affected the clinical spectrum of included patients. Fifth, our study was not population-based. Most participating hospitals are referral centres so milder hospitalised cases might have been missed and this might overestimate the rate of severe courses. In addition, there were only two hospitals from Costa Rica and Iran, representing one-third of the total sample size; they may not be representative of middle-income countries in general. Accordingly, we did not systematically compare risk factors between Canada and the middle-income countries.

A strength of our study includes its multicentre, multinational design covering the first 15 months of the COVID-19 pandemic. The patient population of symptomatic children hospitalised for PCR-confirmed SARS-CoV-2 is well defined and reduces potential biases from including incidental detections of SARS-CoV-2. Finally, this study represents a large yet comprehensive dataset with over 100 severe cases with a WHO severity score ≥6, thereby allowing us to identify differences in risk factor profiles across age subgroups.

In conclusion, we identified several independent risk factors for severe disease in children hospitalised for symptomatic PCR-positive SARS-CoV-2 infection. Based on our analyses, age was not an independent risk factor, but there appears to be a notable age dependence of specific comorbidities that predispose to severe disease, with obesity in adolescence and cardiac, pulmonary and neurological disorders in younger children as the most important underlying comorbidities. Improved understanding of paediatric risk factors for severe SARS-CoV-2 infection among children requiring hospitalisation can help guide management and refine risk-benefit analyses of paediatric vaccination programmes against SARS-CoV-2.

**Author affiliations**

1Department of Pediatrics, McGill University, Montreal, Quebec, Canada
2Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
3Department of Pediatrics, Western University, London, Ontario, Canada
4Department of Pediatrics, Trillium Health Partners, Mississauga, Ontario, Canada
5Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada
6Department of Pediatrics, University of Ottawa, Ottawa, Ontario, Canada
7Department of Pediatrics, Caja Costarricenace de Seguro Social (CCSS), Hospital Nacional de Ninos Dr Carlos Saenz Herrera, San Jose, San Jose, Costa Rica
8Department of Pediatrics, University of Manitoba, Winnipeg, Manitoba, Canada
9Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada
10Department of Pediatrics, Memorial University of Newfoundland, St. John’s, Newfoundland and Labrador, Canada
11Department of Pediatrics, Iran University of Medical Sciences, Tehran, Iran (the Islamic Republic of)
12Department of Pediatrics, Universite de Montreal, Montreal, Quebec, Canada
13Department of Pediatrics, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
14Department of Pediatrics, Queen’s University, Kingston, Ontario, Canada
15British Columbia Children’s Hospital, Vancouver, British Columbia, Canada
16Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada
17Department of Pediatrics, Dalhousie University, Halifax, British Columbia, Canada
18Department of Pediatrics, The University of British Columbia, Vancouver, British Columbia, Canada
19Vaccine Evaluation Center, British Columbia Children’s Hospital, Vancouver, British Columbia, Canada
20Department of Pediatrics, CHU de Quebec-Université Laval, Quebec, Canada
21Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada
22Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada

**Twitter** Tilmann Schober @TilmannSchober, Tammie Dewan @drtammiedewan, Tala El Tal @TalPedsRheum, Peter Gill @peterjgill, Fatima Kakkar @DrFatimaKakkar, Kirk Leifso @leifskro, Luc Panetta @LucPanetta, Manish Sadaranangi @manishs, Arina A Top @drkarinastop, Rolando Ulloa-Gutierrez @rolloandog and Jacqueline Wong @JWong_PedsID

**Contributors** The study was conceived by JL, MB and JP, and supervised by JL and JP. Analysis was conducted by CC, JM and TS. TS wrote the first draft of the manuscript. All authors contributed to data collection and interpretation, reviewed the manuscript critically for important intellectual content, gave final approval of the version to be published and agreed to be accountable for all aspects of the work. JP is responsible for the overall content as guarantor.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None.

**Patient and public involvement** Patients and/or the public were not involved in the design, or conduct, or reporting or dissemination plans of this research.

**Patient consent for publication** Not applicable.

**Ethics approval** Ethics approval was obtained from each participating institution’s ethics research board, with waiver for informed consent for health records research (online supplementary methods).

**Provenance and peer review** Not commissioned; externally peer reviewed.
REFERENCES

1. Delahoy MJ, Ujamaa D, Whitaker M, et al. Hospitalizations Associated with COVID-19 Among Children and Adolescents - COVID-NET, 14 States, March 1, 2020-August 14, 2021. MMWR Morb Mortal Wkly Rep 2021;70:1255–60.

2. Public-Health-England. JCVI issues updated advice on COVID-19 vaccination of children aged 12 to 15 years. Available: https://www.gov.uk/government/news/jcvi-issues-updated-advice-on-covid-19-vaccination-of-children-aged-12-to-15 [Accessed 09 Mar 2021].

3. WHO. COVID-19 vaccines advice. 2021. Available: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/advice [Accessed 29 Sep 2021].

4. Bixler D, Miller AD, Mattison CP, et al. SARS-CoV-2-Associated Deaths Among Persons Aged <21 Years - United States, February 12-July 31, 2020. MMWR Morb Mortal Wkly Rep 2020;69:1324–6.

5. Fernandes DM, Oliveira CR, Guerguis S, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Clinical Syndromes and Predictors of Disease Severity in Hospitalized Children and Youth. J Pediatr 2021;230:e10:23–31.

6. Gutzinger F, Santiago-Garcia B, Noguera-Julián A, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health 2020;4:653–61.

7. Graff K, Smith C, Silveira L, et al. Risk factors for severe COVID-19 in children. Pediatr Infect Dis J 2021;40:e137–45.

8. Kompaniyects L, Agathis NT, Nelson JM, et al. Underlying medical conditions associated with severe COVID-19 illness among children. JAMA Netw Open 2021;4:e2111182.

9. Moreira A, Chorath K, Rajasekaran K, et al. Demographic predictors of hospitalization and mortality in US children with COVID-19. Eur J Pediatr 2021;180:1659–63.

10. Ouldali N, Yang DD, Madhi F, et al. Factors associated with severe SARS-CoV-2 infection. Pediatrics 2021;147. doi:10.1542/peds.2020-023432. [Epub ahead of print: 15 Dec 2020].

11. Zachariah P, Johnson CL, Halabi KC, et al. Epidemiology, clinical features, and disease severity in patients with coronavirus disease 2019 (COVID-19) in a children’s hospital in New York City, New York. JAMA Pediatr 2020;174:e202430.

12. Oliveira EA, Colosimo EA, Simões E Silva AC, et al. Clinical characteristics and risk factors for death among hospitalised children and adolescents with COVID-19 in Brazil: an analysis of a nationwide database. Lancet Child Adolesc Health 2021;5:559–68.

13. Swann OV, Holden KA, Turtle L, et al. Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. BMJ 2020;370:m3249.

14. Drouin O, Hepburn CM, Farrar DS, et al. Characteristics of children admitted to hospital with acute SARS-CoV-2 infection in Canada in 2020. CMAJ 2021;193:E1483–93.

15. Woodruff F, Campbell AP, Taylor CA. Risk factors for severe COVID-19 in children. Pediatrics 2021:e2021053418.

16. Garazzino S, Lo Vecchio A, Pianonti L, et al. Epidemiology, clinical features and prognostic factors of pediatric SARS-CoV-2 infection: results from an Italian multicenter study. Front Pediatr 2021;9:49388.

17. Gates M, Pillay J, Wingert A. Risk factors associated with severe outcomes of COVID-19: an updated rapid review to inform national guidance on vaccine prioritization in Canada. medRxiv 2021.

18. Harris PA, Taylor R, Minor BL, et al. The REDCap Consortium: building an international community of software platform partners. J Biomed Inform 2019;95:103208.

19. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377–81.

20. WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis 2020;20:e19.

21. Young K, Gemmill I, Harrison R. Summary of the NACI seasonal influenza vaccine statement for 2020-2021. Can Commun Dis Rep 2020;46:132–7.

22. Orsini N, Greenland S. A procedure to Tabulate and plot results after flexible modeling of a quantitative covariate. Stata J 2011;11:1–29.

23. STATA. 2022. Available: https://www.stata.com/manuals13/rmk spline.pdf [Accessed 22 May 2022].

24. von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007;370:1453–7.

25. Feldstein LR, Tenforde MW, Friedman KG, et al. Characteristics and outcomes of US children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19. JAMA 2021;325:1074–87.

26. Ernes D, Hüls A, Baumer N, et al. COVID-19 in children with Down syndrome: data from the trisomy 21 research Society survey. J Clin Med 2021;10. doi:10.3390/jcm10215125. [Epub ahead of print: 31 Oct 2021].

27. Statistics-Canada. Table 17-10-0005-01 population estimates on July 1st, by age and sex. Available: https://www15.statcan.gc.ca/t1/1/en/tv.action?pid=1710005051 [Accessed 28 Sep 2021].

28. Burstein B, Anderson G, Yannopoulos A. Prevalence of serious bacterial infections among febrile infants 90 days or younger in a Canadian urban pediatric emergency department during the COVID-19 pandemic. JAMA Netw Open 2021;4:e2116919.

29. Guzman BV, Elbel B, Jay M, et al. Age-Dependent association of obesity with COVID-19 severity in paediatric patients. Pediatr Obes 2022;17:e12856.

30. Williamson EW, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFE. Nature 2020;584:430–6.

31. Al Yazidi LS, Al Hinai Z, Al Waili B, et al. Epidemiology, characteristics and outcomes of children hospitalized with COVID-19 in Oman: a multicenter cohort study. Int J Infect Dis 2021;104:655–60.

32. Schuster JE, de St Maurice A. COVID-19 in Children-Not just little adults. JAMA Netw Open 2021;4:e2111441.

33. Brodin P. Immune determinants of COVID-19 disease presentation and severity. Nat Med 2021;27:28–33.

34. Merckx J, Cooke S, El Tal T, et al. Predictors of severe illness in children with multisystem inflammatory syndrome after SARS-CoV-2 infection: a multicentre cohort study. CAMJ 2022;194:E513–23.